FDA Finishes Review Of Plant Making Johnson & Johnson Vaccine Drug

by ian

 

A U.S. plant that was making Johnson & Johnson’s COVID-19 vaccine must fix a long list of problems to resume operation, according to a highly critical report by the FDA. Experts said addressing the issues raised in the scathing inspection report could take months.

 

Leave a Comment

DONATE NOW